Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yasuhiro Nakamura
Observed name:
Y. Nakamura
Institutions:
Saitama International Medical Center,
Saitama Medical University
Observed institutions:
Saitama International Medical Center,
Saitama Medical University
ORCID:
0000-0002-3664-5818
Observed ORCID:
0000-0002-3664-5818
OpenAlex ID:
A5079218165
Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma
2025
·
Motoki Nakamura
, Dai Ogata
, et al.
·
British Journal of Dermatology
·
5
809P Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy
2022
·
S.K. Jacques
, J. McKeown
, et al.
·
Annals of Oncology
·
4
Real‐World Efficacy of Chemotherapy in Patients With Advanced Unresectable Extramammary Paget Disease: A Retrospective Multicenter Study of 138 Japanese Patients
2025
·
Azusa Miyashita
, Satoshi Fukushima
, et al.
·
The Journal of Dermatology
·
2
PDF
Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors
2026
·
Kazuhiro Aoyama
, Shusuke Kawashima
, et al.
·
Journal of Investigative Dermatology
·
1
Adjuvant treatment for acral melanoma
2026
·
Takaya Komori
, Yasuhiro Nakamura
·
Journal of the European Academy of Dermatology and Venereology
Examining real world efficacy and toxicity of adjuvant targeted therapy in old vs younger patients with stage III melanoma
2025
·
K. Connors
, A. Williamson
, et al.
·
EJC Skin Cancer
Adjuvant therapy for Asian patients with resected stage III/IV BRAF V600-mutant melanoma with more than 3 years of follow-up: A multicenter retrospective study in Japan
2024
·
K. Namikawa
, S. Mori
, et al.
·
EJC Skin Cancer
Show more works
View as search
Works count:
7
Citation count:
12
H-index:
2
I10-index:
Year
Topic
Type